<DOC>
	<DOCNO>NCT01244217</DOCNO>
	<brief_summary>Primary Objective : - To evaluate safety ( 4 week ) Secondary Objectives : - To evaluate long-term safety ( 12 week ) - To evaluate efficacy - To characterize pharmacokinetic profile</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetic Study Allegra Pediatric Patients With Perennial Allergic Rhinitis ( PAR )</brief_title>
	<detailed_description>The study consist four phase : 9-day screening phase , main 4-week treatment phase , up-to 8-week extension phase , up-to 5-day post-treatment phase .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<criteria>Inclusion criterion : Aged 6 month 11 year Patients perennial allergic rhinitis Exclusion criterion : Neither serum specific IgE antibody skin reaction positive antigen perennial allergy . Nasal symptom score 0 either sneeze nasal discharge , sum two score less 3 , nasal congestion score 4 . Patients vasomotor rhinitis eosinophilic rhinitis . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>